文献速递医学人工智能与信息学基础与转化研究

基于人工智能的血液检测设备用于急性感染与脓毒症诊断及预后判断的临床验证

Clinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis.
PubMed 文献 · Nat Med · 2025-09-30

研究开发了TriVerity,通过等温扩增29种mRNA并结合机器学习算法,在Myrna仪器上判断细菌感染、病毒感染及7天内需重症监护干预的可能性。SEPSIS-SHIELD研究纳入1,222例患者,以临床裁定感染状态和7天内需重症干预为终点进行验证。TriVerity细菌和病毒评分诊断准确性高于C反应蛋白、降钙素原或白细胞计数,严重度评分预测疾病严重程度并可重新分类风险,但需介入性临床测试证明其可操作性和临床获益。

要点

  • TriVerity细菌和病毒评分诊断细菌感染AUROC为0.83,诊断病毒感染AUROC为0.91,准确性高于C反应蛋白、降钙素原或白细胞计数。
  • TriVerity严重度评分预测疾病严重程度AUROC为0.78,与单独临床评估(qSOFA)相比可重新分类需重症监护干预的风险。
  • 三个评分规则纳入特异性均>92%,规则排除敏感性均>95%;TriVerity可能将不当抗生素使用的假阳性和假阴性减少60-70%。

核心结论

  • TriVerity对细菌感染、病毒感染和疾病严重程度具有较高诊断和预后准确性,可能减少不当抗生素使用的假阳性和假阴性,但需介入性临床测试证明其可操作性和临床获益。

研究设计与样本

  • 开发TriVerity,利用等温扩增29种mRNA和机器学习算法在Myrna仪器上判断细菌感染、病毒感染及7天内需重症监护干预的可能性。
  • SEPSIS-SHIELD研究纳入1,222例患者,以临床裁定感染状态和7天内需重症监护干预为终点进行验证。

主要发现

  • TriVerity细菌和病毒评分诊断细菌感染的AUROC为0.83,诊断病毒感染的AUROC为0.91,准确性高于C反应蛋白、降钙素原或白细胞计数。
  • TriVerity严重度评分预测疾病严重程度的AUROC为0.78,与单独临床评估(qSOFA)相比可重新分类需重症监护干预的风险。
  • 三个评分的规则纳入特异性均>92%,规则排除敏感性均>95%。
  • 比较就诊时抗生素给药与随访后裁定发现,TriVerity可能将不当抗生素使用的假阳性和假阴性减少60-70%。

关键数值与推荐

  • 细菌感染诊断AUROC为0.83,病毒感染诊断AUROC为0.91,严重程度预测AUROC为0.78。
  • 三个评分规则纳入特异性>92%,规则排除敏感性>95%。
  • TriVerity可能将不当抗生素使用的假阳性和假阴性减少60-70%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需在介入性环境中进一步临床测试以证明TriVerity的可操作性和临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lack of reliable diagnostics for the presence, type and severity of infection in patients presenting to emergency departments with non-specific symptoms poses considerable challenges. We developed TriVerity, which uses isothermal amplification of 29 mRNAs and machine learning algorithms on the Myrna instrument to determine likelihoods of bacterial infection, viral infection and need for critical care interventions within 7 days. To validate TriVerity, the SEPSIS-SHIELD study enrolled 1,222 patients with clinically adjudicated infection status and need for critical care intervention within 7 days as endpoints. The TriVerity Bacterial and Viral scores had higher accuracy than C-reactive protein, procalcitonin or white blood cell count for the diagnosis of bacterial infection with area under the receiver operating characteristic (AUROC) of 0.83, and viral infection (AUROC = 0.91). The TriVerity Severity score had an AUROC of 0.78 for predicting illness severity and allowed reclassification of risk for critical care interventions compared to clinical assessment (quick Sequential Organ Failure Assessment) alone. Each of the three scores had rule-in specificity >92% and rule-out sensitivity >95%. Comparison of antibiotics administration at presentation with post-follow-up adjudication found that TriVerity could potentially reduce false positives and false negatives for inappropriate antibiotics use by 60-70%. Further clinical testing in an interventional setting is needed to prove actionability and clinical benefit of TriVerity.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Liesenfeld O, Arora S, Aufderheide TP, et al. Clinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis. Nat Med. 2025. PMID: 41028541. doi:10.1038/s41591-025-03933-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。